Ventrus Biosciences (NASDAQ:VTUS)

CAPS Rating: 2 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar NuclearSteve (55.83) Submitted: 4/12/2013 2:08:35 PM : Outperform Start Price: $2.80 VTUS Score: -9.25

Baker brothers increased their holding.

Recs

0
Member Avatar carefulguy (< 20) Submitted: 11/16/2011 1:37:23 AM : Outperform Start Price: $8.15 VTUS Score: -99.81

Currently undervalued based on large market potential of a Hemorrhoids treatment (first to market - currently no treatment available). Good cash balance, and upcoming Q2 2012 PIII pivotal clinical trial results of two drugs. Currently trading at very low volume, once interest picks up, pps will go up.

Recs

0
Member Avatar corkbouy (77.78) Submitted: 7/21/2011 4:38:10 PM : Outperform Start Price: $11.68 VTUS Score: -100.20

The clearance will soon come from the fed. for this the first drug of its kind. Now Dr.s can prescribe a med for this type of problem.

Recs

0
Member Avatar ferdicemara (< 20) Submitted: 6/6/2011 9:30:32 AM : Outperform Start Price: $16.73 VTUS Score: -111.38

10000

Recs

0
Member Avatar EclecticRecluse (77.84) Submitted: 5/16/2011 7:36:54 AM : Underperform Start Price: $19.47 VTUS Score: +110.11

High Price with Low Professional Opinion

Results 1 - 5 of 5

Featured Broker Partners


Advertisement